Trials / Completed
CompletedNCT00726115
Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531
Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAM-531 | |
| DRUG | placebo |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-07-31
- Last updated
- 2009-07-30
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00726115. Inclusion in this directory is not an endorsement.